Last edition
News about "Samsung Biologics acquisition"
Samsung Biologics to Acquire PolyPeptide in All-Cash Deal
Samsung Biologics has launched a CHF 1.46 billion all-cash offer to acquire PolyPeptide, expanding its global CDMO network and multi-modality strategy.
Samsung Biologics Acquisition | 23/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members